| Code | CSB-RA006163MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to WBP299, targeting CTLA4 (Cytotoxic T-Lymphocyte Associated protein 4), a critical immune checkpoint receptor expressed primarily on T cells. CTLA4 functions as a negative regulator of T cell activation by competing with the costimulatory receptor CD28 for binding to B7 ligands (CD80/CD86) on antigen-presenting cells. By delivering inhibitory signals, CTLA4 maintains immune homeostasis and prevents excessive immune responses. Dysregulation of CTLA4 signaling is implicated in various conditions, including autoimmune diseases, transplant rejection, and cancer, where tumors exploit this checkpoint to evade immune surveillance.
WBP299 serves as the reference antibody for this biosimilar product, providing researchers with a reliable tool for investigating CTLA4-mediated immune regulation. This antibody is valuable for studies examining T cell function, immune checkpoint mechanisms, tumor immunology, and the development of immunotherapeutic strategies. It enables researchers to explore CTLA4's role in immune modulation and its therapeutic potential across various disease models.
There are currently no reviews for this product.